Michel C Nussenzweig

List of Publications by Year in Descending Order

265 papers	41,399 citations	100 h-index	202 g-index
301 ext. papers	52,888 ext. citations	25.4 avg, IF	7.46 L-index

#	Paper	IF	Citations
265	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	1
264	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.. *Lancet Microbe, The*, **2022**, 3, e203-e214	22.2	2
263	Germinal Centers.. *Annual Review of Immunology*, **2022**,	34.7	14
262	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. **2022**,		1
261	Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer.. *Nature Communications*, **2022**, 13, 732	17.4	1
260	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. **2022**,		3
259	The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.. *Trials*, **2022**, 23, 263	2.8	0
258	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. *Immunity*, **2022**,	32.3	10
257	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. *Nature*, **2022**,	50.4	14
256	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2200413119	11.5	3
255	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. *New England Journal of Medicine*, **2021**,	59.2	93
254	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. **2021**,		31
253	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. *Science Translational Medicine*, **2021**, 13, eabk1533	17.5	4
252	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. *Nature*, **2021**,	50.4	69
251	Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope. *Npj Vaccines*, **2021**, 6, 126	9.5	0
250	Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation. *Cell Reports*, **2021**, 37, 109942	10.6	3
249	Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence. *Journal of Experimental Medicine*, **2021**, 218,	16.6	3

248	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *Journal of Experimental Medicine*, **2021**, 218,	16.6	171
247	Evolution of Antibody Immunity to SARS-CoV-2 **2021**,		43
246	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice **2021**,		4
245	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. *EBioMedicine*, **2021**, 65, 103252	8.8	5
244	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies **2021**,		24
243	Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants **2021**,		8
242	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. *Nature*, **2021**, 593, 424-428	50.4	36
241	A humanized mouse model of chronic COVID-19 to evaluate disease mechanisms and treatment options **2021**,		1
240	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies **2021**,		27
239	Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. *Journal of Experimental Medicine*, **2021**, 218,	16.6	6
238	TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. *Clinical Chemistry*, **2021**, 67, 1249-1258	5.5	5
237	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies **2021**,		13
236	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year **2021**,		19
235	Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. *Aids*, **2021**, 35, 1567-1574	3.5	3
234	Sequencing, cloning, and antigen binding analysis of monoclonal antibodies isolated from single mouse B cells. *STAR Protocols*, **2021**, 2, 100389	1.4	1
233	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*, **2021**, 595, 426-431	50.4	247
232	Germinal center-dependent and -independent memory B cells produced throughout the immune response. *Journal of Experimental Medicine*, **2021**, 218,	16.6	14
231	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. *Nature*, **2021**, 595, 278-282	50.4	49

230	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *New England Journal of Medicine*, **2021**, 384, 2212-2218	59.2	347
229	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. *PLoS Pathogens*, **2021**, 17, e1009688	7.6	7
228	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. *Nature Communications*, **2021**, 12, 4196	17.4	106
227	Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Science Translational Medicine*, **2021**, 13,	17.5	178
226	Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia. *Journal of Experimental Medicine*, **2021**, 218,	16.6	9
225	Evolution of antibody immunity to SARS-CoV-2. *Nature*, **2021**, 591, 639-644	50.4	652
224	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice **2021**,		5
223	Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease **2021**,		2
222	Persistent cellular immunity to SARS-CoV-2 infection. *Journal of Experimental Medicine*, **2021**, 218,	16.6	59
221	TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability **2021**,		2
220	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. *Science*, **2021**, 371, 735-741	33.3	130
219	Dynamic regulation of T selection during the germinal centre reaction. *Nature*, **2021**, 591, 458-463	50.4	19
218	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*, **2021**, 592, 616-622	50.4	730
217	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York **2021**,		54
216	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. *Journal of Virology*, **2021**, 95,	6.6	11
215	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. *Cell Reports*, **2021**, 36, 109450	10.6	23
214	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. *Nature Communications*, **2021**, 12, 4886	17.4	30
213	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. *Immunity*, **2021**, 54, 1853-1868.e7	32.3	83

212	Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths. *Science Immunology*, **2021**, 6,	28	91
211	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. *Cell Reports*, **2021**, 36, 109760	10.6	29
210	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. *Nature*, **2021**,	50.4	65
209	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants **2021**,		54
208	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. *Science Translational Medicine*, **2021**, 13,	17.5	14
207	A humanized mouse model of chronic COVID-19.. *Nature Biotechnology*, **2021**,	44.5	8
206	Single-Cell Sorting of HBsAg-Binding Memory B Cells from Human Peripheral Blood Mononuclear Cells and Antibody Cloning. *STAR Protocols*, **2020**, 1, 100129	1.4	1
205	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell*, **2020**, 182, 828-842.e16	56.2	485
204	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. *Cell Host and Microbe*, **2020**, 28, 335-349.e6	23.4	25
203	Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies. *Nature Communications*, **2020**, 11, 3195	17.4	6
202	A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 7981-7989	11.5	11
201	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. *Journal of Virology*, **2020**, 94,	6.6	18
200	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *ELife*, **2020**, 9,	8.9	784
199	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants **2020**,		31
198	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. *ELife*, **2020**, 9,	8.9	6
197	Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. *Nature Medicine*, **2020**, 26, 222-227	50.5	50
196	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals **2020**,		60
195	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies **2020**,		30

194	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses **2020**,		35
193	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants **2020**,		32
192	Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies **2020**,		18
191	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro **2020**,		15
190	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection **2020**,		21
189	Persistent Cellular Immunity to SARS-CoV-2 Infection **2020**,		9
188	Isolation of single HIV-1 Envelope specific B cells and antibody cloning from immunized rhesus macaques. *Journal of Immunological Methods*, **2020**, 478, 112734	2.5	12
187	ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. *Cell Reports Medicine*, **2020**, 1, 100123	18	46
186	Nanoparticles presenting clusters of CD4 expose a universal vulnerability of HIV-1 by mimicking target cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 18719-18728	11.5	11
185	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature*, **2020**, 588, 682-687	50.4	651
184	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*, **2020**, 584, 437-442	50.4	1167
183	Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration. *Antibodies*, **2020**, 9,	7	3
182	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *Journal of Experimental Medicine*, **2020**, 217,	16.6	289
181	Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. *Journal of Experimental Medicine*, **2020**, 217,	16.6	34
180	Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates. *Cell*, **2020**, 183, 1298-1311.e11	56.2	59
179	An apoptosis-dependent checkpoint for autoimmunity in memory B and plasma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 24957-24963	11.5	5
178	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*, **2020**, 370,	33.3	994
177	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science*, **2020**, 370,	33.3	1090

176	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. *Nature Medicine*, **2020**, 26, 1339-1350	50.5	43
175	Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 9865-9875	11.5	5
174	Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates. *Journal of Virology*, **2020**,	6.6	11
173	Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption. *Journal of Virology*, **2019**, 93,	6.6	31
172	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. *Immunity*, **2019**, 50, 1513-1529.e9	32.3	53
171	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. *Nature*, **2019**, 570, 468-473	50.4	95
170	HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. *Journal of Experimental Medicine*, **2019**, 216, 1301-1310	16.6	36
169	Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. *Nature Medicine*, **2019**, 25, 547-553	50.5	126
168	Risk of Zika microcephaly correlates with features of maternal antibodies. *Journal of Experimental Medicine*, **2019**, 216, 2302-2315	16.6	28
167	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. *PLoS ONE*, **2019**, 14, e0219142	3.7	33
166	Protein Amounts of the MYC Transcription Factor Determine Germinal Center B Cell Division Capacity. *Immunity*, **2019**, 51, 324-336.e5	32.3	56
165	Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses. *Journal of Experimental Medicine*, **2019**, 216, 2316-2330	16.6	12
164	Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. *Journal of Experimental Medicine*, **2019**, 216, 2253-2264	16.6	42
163	Editorial Board: Expanding on the basis of cancer. *Journal of Experimental Medicine*, **2019**, 216, 1725	16.6	
162	Clonal CD4 T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. *Nature Medicine*, **2018**, 24, 604-609	50.5	72
161	A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. *Nature Medicine*, **2018**, 24, 610-616	50.5	71
160	Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4743-4748	11.5	53
159	Redemption for self-reactive antibodies. *Science*, **2018**, 360, 152-153	33.3	4

158	Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. *Nature Communications*, **2018**, 9, 1251	17.4	58
157	Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. *Journal of Experimental Medicine*, **2018**, 215, 2311-2324	16.6	55
156	Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency. *Nature Immunology*, **2018**, 19, 973-985	19.1	67
155	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. *PLoS Pathogens*, **2018**, 14, e1006860	7.6	42
154	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. *Journal of Virology*, **2018**, 92,	6.6	32
153	Relationship between intact HIV-1 proviruses in circulating CD4 T cells and rebound viruses emerging during treatment interruption. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E11341-E11348	11.5	42
152	A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. *Cell Reports*, **2018**, 25, 1385-1394.e7	10.6	43
151	The Chromatin Reader ZMYND8 Regulates Igh Enhancers to Promote Immunoglobulin Class Switch Recombination. *Molecular Cell*, **2018**, 72, 636-649.e8	17.6	15
150	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. *Nature*, **2018**, 561, 479-484	50.4	250
149	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. *Nature Medicine*, **2018**, 24, 1701-1707	50.5	142
148	Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. *Cell Host and Microbe*, **2018**, 24, 579-592.e4	23.4	51
147	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. *Science Translational Medicine*, **2017**, 9,	17.5	96
146	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. *Nature Medicine*, **2017**, 23, 185-191	50.5	282
145	RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks. *Journal of Experimental Medicine*, **2017**, 214, 815-831	16.6	10
144	Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. *Cell*, **2017**, 169, 597-609.e11	36.2	199
143	HIV: Persistence through division. *Journal of Experimental Medicine*, **2017**, 214, 875-876	16.6	2
142	Early antibody therapy can induce long-lasting immunity to SHIV. *Nature*, **2017**, 543, 559-563	50.4	162
141	Progress toward active or passive HIV-1 vaccination. *Journal of Experimental Medicine*, **2017**, 214, 3-16	16.6	94

140	The cell cycle restricts activation-induced cytidine deaminase activity to early G1. *Journal of Experimental Medicine*, **2017**, 214, 49-58	16.6	39
139	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. *Journal of Experimental Medicine*, **2017**, 214, 2573-2590	16.6	100
138	The microanatomic segregation of selection by apoptosis in the germinal center. *Science*, **2017**, 358,	33.3	114
137	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. *Cell*, **2017**, 170, 637-648.e10	56.2	93
136	JEM Advisory Editorial Board: Increasing diversity. *Journal of Experimental Medicine*, **2017**, 214, 2169	16.6	0
135	The new face of JEM. *Journal of Experimental Medicine*, **2017**, 214, 3467	16.6	
134	Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. *ELife*, **2017**, 6,	8.9	37
133	Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E7908-E7916	11.5	117
132	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. *Nature Structural and Molecular Biology*, **2016**, 23, 906-915	17.6	143
131	Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. *Nature Protocols*, **2016**, 11, 1908-1923	18.8	83
130	Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs. *Journal of Experimental Medicine*, **2016**, 213, 2861-2870	16.6	87
129	Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. *New England Journal of Medicine*, **2016**, 375, 2019-2021	59.2	55
128	Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. *Cell*, **2016**, 165, 1609-1620	56.2	103
127	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. *Nature* , **2016**, 535, 556-60	50.4	298
126	Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation. *Journal of Experimental Medicine*, **2016**, 213, 517-34	16.6	81
125	A New Way to Diversify Antibodies by DNA Transposition. *Cell*, **2016**, 164, 601-2	56.2	2
124	Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. *Journal of Clinical Investigation*, **2016**, 126, 415-23	15.9	50
123	Structural basis for germline antibody recognition of HIV-1 immunogens. *ELife*, **2016**, 5,	8.9	48

122	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. *PLoS Pathogens*, **2016**, 12, e1005520	7.6	106
121	Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. *Nature Communications*, **2016**, 7, 10618	17.4	117
120	Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory. *Immunity*, **2016**, 44, 769-81	32.3	79
119	Inducible targeting of cDCs and their subsets in vivo. *Journal of Immunological Methods*, **2016**, 434, 32-8	2.5	38
118	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. *Science*, **2016**, 352, 997-1001	33.3	202
117	Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. *Science*, **2016**, 352, 1001-4	33.3	240
116	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. *Nature*, **2016**, 533, 105-109	50.4	229
115	Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. *Cell*, **2016**, 166, 1445-1458.e12	56.2	204
114	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. *Immunity*, **2016**, 45, 483-496	32.3	232
113	Circulating precursors of human CD1c+ and CD141+ dendritic cells. *Journal of Experimental Medicine*, **2015**, 212, 401-13	16.6	154
112	HUMORAL IMMUNITY. T cell help controls the speed of the cell cycle in germinal center B cells. *Science*, **2015**, 349, 643-6	33.3	137
111	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. *Cell*, **2015**, 161, 1505-15	56.2	197
110	Collecting lymphatic vessel permeability facilitates adipose tissue inflammation and distribution of antigen to lymph node-homing adipose tissue dendritic cells. *Journal of Immunology*, **2015**, 194, 5200-10	5.3	84
109	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. *Nature*, **2015**, 522, 487-91	50.4	509
108	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. *Nature Communications*, **2015**, 6, 8167	17.4	62
107	Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma. *Cell*, **2015**, 162, 727-37	56.2	98
106	Defining human dendritic cell progenitors by multiparametric flow cytometry. *Nature Protocols*, **2015**, 10, 1407-22	18.8	44
105	Orientation-specific joining of AID-initiated DNA breaks promotes antibody class switching. *Nature*, **2015**, 525, 134-139	50.4	76

104	Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. *MBio*, **2015**, 6,	7.8	19
103	Clonal analysis of human dendritic cell progenitor using a stromal cell culture. *Journal of Immunological Methods*, **2015**, 425, 21-26	2.5	25
102	An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex. *Journal of Allergy and Clinical Immunology*, **2015**, 135, 998-1007.e6	11.5	30
101	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. *PLoS Pathogens*, **2015**, 11, e1005238	7.6	36
100	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. *Cell*, **2015**, 161, 1280-92	56.2	219
99	Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. *Journal of Experimental Medicine*, **2015**, 212, 385-99	16.6	185
98	Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient. *Journal of Immunological Methods*, **2015**, 418, 61-5	2.5	5
97	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. *Nature*, **2015**, 519, 87-91	50.4	211
96	Intra-spike crosslinking overcomes antibody evasion by HIV-1. *Cell*, **2015**, 160, 433-46	56.2	84
95	HIV-1 integration landscape during latent and active infection. *Cell*, **2015**, 160, 420-32	56.2	289
94	Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. *Journal of Virology*, **2015**, 89, 2659-71	6.6	101
93	L-Myc expression by dendritic cells is required for optimal T-cell priming. *Nature*, **2014**, 507, 243-7	50.4	58
92	Clonal selection in the germinal centre by regulated proliferation and hypermutation. *Nature*, **2014**, 509, 637-40	50.4	364
91	A robust pipeline for rapid production of versatile nanobody repertoires. *Nature Methods*, **2014**, 11, 1253-60	25.0	253
90	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. *Journal of Experimental Medicine*, **2014**, 211, 2061-74	16.6	245
89	Identification of chromosomal translocation hotspots via scan statistics. *Bioinformatics*, **2014**, 30, 2551-8	7.2	10
88	Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. *Journal of Experimental Medicine*, **2014**, 211, 1875-91	16.6	68
87	Dynamic signaling by T follicular helper cells during germinal center B cell selection. *Science*, **2014**, 345, 1058-62	33.3	246

86	Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. *Cell*, **2014**, 158, 989-999	56.2	283
85	Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. *Cell*, **2014**, 158, 1243-1253	56.2	338
84	Structural insights on the role of antibodies in HIV-1 vaccine and therapy. *Cell*, **2014**, 156, 633-48	56.2	268
83	Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. *Cell Reports*, **2014**, 7, 785-95	10.6	180
82	Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo. *Journal of Immunology*, **2014**, 192, 5830-8	5.3	43
81	Epigenetic targeting of activation-induced cytidine deaminase. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 18667-72	11.5	37
80	Adaptation of HIV-1 Envelope Glycoprotein gp120 to Humoral Immunity over the Course of the Epidemic. *AIDS Research and Human Retroviruses*, **2014**, 30, A224-A224	1.6	
79	Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. *Cell*, **2014**, 159, 1538-48	56.2	176
78	B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. *Cell*, **2014**, 159, 1524-37	56.2	186
77	Engineering Antibodies to Enhance Activity and Increase Half-life. *AIDS Research and Human Retroviruses*, **2014**, 30, A210-A210	1.6	2
76	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. *Journal of Experimental Medicine*, **2014**, 211, 2361-72	16.6	67
75	Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. *Immunity*, **2013**, 39, 245-58	32.3	254
74	Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160□(BaL.). *Journal of Immunological Methods*, **2013**, 397, 47-54	2.5	8
73	T follicular helper cell dynamics in germinal centers. *Science*, **2013**, 341, 673-7	33.3	226
72	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 16538-43	11.5	208
71	Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. *Nature*, **2013**, 503, 224-8	50.4	489
70	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. *Nature*, **2013**, 503, 277-80	50.4	359
69	Antibodies in HIV-1 vaccine development and therapy. *Science*, **2013**, 341, 1199-204	33.3	361

68	Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 6049-54	11.5	45
67	Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. *Annual Review of Pathology: Mechanisms of Disease*, **2013**, 8, 79-103	34	125
66	Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. *Cell*, **2013**, 153, 126-38	56.2	376
65	Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. *Journal of Virology*, **2013**, 87, 8535-44	6.6	20
64	Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. *Journal of Experimental Medicine*, **2013**, 210, 2813-21	16.6	121
63	Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 10598-603	11.5	82
62	Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. *Journal of Virology*, **2013**, 87, 10047-58	6.6	54
61	Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. *Journal of Experimental Medicine*, **2013**, 210, 1235-49	16.6	76
60	Translocation capture sequencing: a method for high throughput mapping of chromosomal rearrangements. *Journal of Immunological Methods*, **2012**, 375, 176-81	2.5	21
59	Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. *Blood*, **2012**, 120, 2240-8	2.2	242
58	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. *Nature*, **2012**, 492, 118-22	50.4	401
57	A Blueprint for HIV Vaccine Discovery. *Cell Host and Microbe*, **2012**, 12, 396-407	23.4	302
56	The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. *Nature Immunology*, **2012**, 13, 1083-91	19.1	275
55	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. *Journal of Experimental Medicine*, **2012**, 209, 1469-79	16.6	131
54	Germinal centers. *Annual Review of Immunology*, **2012**, 30, 429-57	34.7	1346
53	Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. *Journal of Experimental Medicine*, **2012**, 209, 1153-65	16.6	356
52	Polyreactive antibodies in adaptive immune responses to viruses. *Cellular and Molecular Life Sciences*, **2012**, 69, 1435-45	10.3	81
51	Enhanced HIV-1 neutralization by antibody heteroligation. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 875-80	11.5	49

50	Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E2083-90	11.5	168
49	A mouse model for HIV-1 entry. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 15859-64	11.5	67
48	Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E3268-77	11.5	409
47	Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. *Science*, **2011**, 333, 1633-7	33.3	874
46	Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. *PLoS ONE*, **2011**, 6, e24078	3.7	88
45	Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. *Cell*, **2011**, 147, 95-106	56.2	286
44	Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 18044-8	11.5	61
43	A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. *Journal of Experimental Medicine*, **2011**, 208, 1243-52	16.6	263
42	Increasing the potency and breadth of an HIV antibody by using structure-based rational design. *Science*, **2011**, 334, 1289-93	33.3	307
41	Ralph Steinman (1943-2011). *Nature*, **2011**, 478, 460	50.4	7
40	Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. *Nature*, **2010** , 467, 591-5	50.4	332
39	Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. *Journal of Virology*, **2010**, 84, 5032-42	6.6	46
38	Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. *Journal of Experimental Medicine*, **2010**, 207, 1995-2002	16.6	53
37	Origin of chromosomal translocations in lymphoid cancer. *Cell*, **2010**, 141, 27-38	56.2	226
36	Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. *Cell*, **2010**, 143, 592-605	56.2	801
35	Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. *Science*, **2010**, 329, 811-7	33.3	871
34	Development and migration of plasma cells in the mouse lymph node. *Immunity*, **2010**, 33, 118-27	32.3	98
33	Germinal center reutilization by newly activated B cells. *Journal of Experimental Medicine*, **2009**, 206, 2907-14	16.6	76

32	A method for identification of HIV gp140 binding memory B cells in human blood. *Journal of Immunological Methods*, **2009**, 343, 65-7	2.5	171
31	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. *Nature*, **2009**, 458, 636-40	50.4	695
30	AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. *Molecular Cell*, **2009**, 36, 631-41	17.6	201
29	Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. *Journal of Immunological Methods*, **2008**, 329, 112-24	2.5	702
28	AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. *Cell*, **2008**, 135, 1028-38	56.2	338
27	Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 9727-32	11.5	169
26	Autoreactivity in human IgG+ memory B cells. *Immunity*, **2007**, 26, 205-13	32.3	364
25	T-independent type II immune responses generate memory B cells. *Journal of Experimental Medicine*, **2006**, 203, 305-10	16.6	204
24	Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase. *Journal of Experimental Medicine*, **2004**, 199, 1235-44	16.6	189
23	Predominant autoantibody production by early human B cell precursors. *Science*, **2003**, 301, 1374-7	33.3	1483
22	OcaB regulates transitional B cell selection. *International Immunology*, **2003**, 15, 1099-104	4.9	19
21	Role of antigen receptor affinity in T cell-independent antibody responses in vivo. *Nature Immunology*, **2002**, 3, 399-406	19.1	196
20	Role of BCR affinity in T cell dependent antibody responses in vivo. *Nature Immunology*, **2002**, 3, 570-5	19.1	226
19	AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching. *Nature*, **2001**, 414, 660-665	50.4	428
18	Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. *Journal of Experimental Medicine*, **2001**, 194, 769-79	16.6	1501
17	Immunoglobulins and B cell development. *Biochemical Society Transactions*, **2000**, 28, A487-A487	5.1	
16	Circulating human B cells that express surrogate light chains and edited receptors. *Nature Immunology*, **2000**, 1, 207-13	19.1	100
15	Antibody regulation of B cell development. *Nature Immunology*, **2000**, 1, 379-85	19.1	199

14	DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. *Nature*, **2000**, 404, 510-4	50.4	458
13	The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. *Journal of Cell Biology*, **2000**, 151, 673-84	7.3	444
12	A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. *Human Immunology*, **2000**, 61, 729-38	2.3	106
11	Secondary V(D)J recombination in B-1 cells. *Nature*, **1999**, 397, 355-9	50.4	62
10	V(D)J recombination: modulation of RAG1 and RAG2 cleavage activity on 12/23 substrates by whole cell extract and DNA-bending proteins. *Journal of Experimental Medicine*, **1997**, 185, 2025-32	16.6	121
9	Requirement for Ku80 in growth and immunoglobulin V(D)J recombination. *Nature*, **1996**, 382, 551-5	50.4	565
8	The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes. *Nature*, **1996**, 383, 542-7	50.4	208
7	The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. *Nature*, **1995**, 375, 151-5	50.4	785
6	Analysis of HIV-1 latent reservoir and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117		1
5	Antigen responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir		3
4	Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates		2
3	Characterization of intact proviruses in blood and lymph node from HIV-infected individuals undergoing analytical treatment interruption		1
2	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
1	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies		7